JP2023512833A5 - - Google Patents
Info
- Publication number
- JP2023512833A5 JP2023512833A5 JP2022548143A JP2022548143A JP2023512833A5 JP 2023512833 A5 JP2023512833 A5 JP 2023512833A5 JP 2022548143 A JP2022548143 A JP 2022548143A JP 2022548143 A JP2022548143 A JP 2022548143A JP 2023512833 A5 JP2023512833 A5 JP 2023512833A5
- Authority
- JP
- Japan
- Prior art keywords
- orf
- mrna
- composition according
- optionally
- sequence listing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062971834P | 2020-02-07 | 2020-02-07 | |
| US62/971,834 | 2020-02-07 | ||
| US202063058463P | 2020-07-29 | 2020-07-29 | |
| US63/058,463 | 2020-07-29 | ||
| US202063130581P | 2020-12-24 | 2020-12-24 | |
| US63/130,581 | 2020-12-24 | ||
| PCT/US2021/017149 WO2021159118A2 (en) | 2020-02-07 | 2021-02-08 | Composition and method of mrna vaccines against novel coronavirus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023512833A JP2023512833A (ja) | 2023-03-29 |
| JP2023512833A5 true JP2023512833A5 (https=) | 2024-02-19 |
Family
ID=77200778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548143A Pending JP2023512833A (ja) | 2020-02-07 | 2021-02-08 | 新型コロナウイルス感染症に対するｍＲＮＡワクチンの組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12029786B2 (https=) |
| EP (1) | EP4100066A4 (https=) |
| JP (1) | JP2023512833A (https=) |
| KR (1) | KR20220143684A (https=) |
| CN (1) | CN115297892A (https=) |
| AU (1) | AU2021216443A1 (https=) |
| BR (1) | BR112022015626A2 (https=) |
| CA (1) | CA3167257A1 (https=) |
| IL (1) | IL295360A (https=) |
| MX (1) | MX2022009688A (https=) |
| WO (1) | WO2021159118A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12029786B2 (en) | 2020-02-07 | 2024-07-09 | RNAimmune, Inc. | Composition and method of mRNA vaccines against novel coronavirus infection |
| WO2021160887A1 (en) * | 2020-02-14 | 2021-08-19 | Immunor As | Corona virus vaccine |
| JPWO2021181994A1 (https=) * | 2020-03-10 | 2021-09-16 | ||
| US20230313323A1 (en) * | 2020-03-26 | 2023-10-05 | Ionian Technologies, Llc | Assays for detecting coronavirus disease 2019 (covid-19) |
| IL297419B2 (en) | 2020-04-22 | 2025-02-01 | BioNTech SE | Coronavirus vaccine |
| WO2021229270A1 (es) | 2020-05-13 | 2021-11-18 | Laboratorio Avi-Mex, S.A. De C.V. | Vacuna recombinante contra covid-19 en vector viral |
| EP4334479A4 (en) * | 2021-05-06 | 2025-02-19 | Lu, Shi-Long | DETECTION OF VIRAL VARIANTS |
| JP2024530672A (ja) | 2021-08-11 | 2024-08-23 | アールエヌエーイミューン、インコーポレイテッド | 新規なコロナウイルス感染症に対するｍＲＮＡワクチンの組成物および方法 |
| WO2023020939A1 (en) * | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| CN118475371A (zh) * | 2021-09-22 | 2024-08-09 | 圣诺制药公司 | 基于组氨酸-赖氨酸共聚物形成的改善的纳米颗粒制剂 |
| WO2023049814A2 (en) * | 2021-09-22 | 2023-03-30 | Sirnaomics, Inc. | Nanoparticle pharmaceutical compositions with reduced nanoparticle size and improved polydispersity index |
| CN113881806A (zh) * | 2021-09-23 | 2022-01-04 | 华南理工大学 | 基于CRISPR/Cas12a技术检测新冠病毒和69/70突变株的方法及试剂盒 |
| EP4183409A1 (en) * | 2021-11-17 | 2023-05-24 | Charité - Universitätsmedizin Berlin | Vaccine with improved immunogenicity against mutant coronaviruses |
| WO2023091766A2 (en) * | 2021-11-19 | 2023-05-25 | RNAimmune, Inc. | Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines |
| AU2022398292A1 (en) * | 2021-11-29 | 2024-06-13 | BioNTech SE | Coronavirus vaccine |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| CN118556131A (zh) | 2022-01-27 | 2024-08-27 | 爱思开生物科技有限公司 | 用于蛋白质表达的mRNA及其模板 |
| US20250228929A1 (en) * | 2022-04-03 | 2025-07-17 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant |
| US20240207389A1 (en) * | 2022-04-27 | 2024-06-27 | Northwestern University | Methods for improving covid vaccine immunogenicity |
| DE102023002588A1 (de) * | 2022-06-26 | 2024-01-25 | BioNTech SE | Coronavirus-Impfstoff |
| WO2024002985A1 (en) * | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| US12280104B2 (en) | 2022-11-01 | 2025-04-22 | RNAimmune, Inc. | Composition and methods for MRNA vaccines against novel omicron coronavirus infections |
| KR102832944B1 (ko) * | 2024-12-27 | 2025-07-15 | 대한민국 | 제2형 중증급성호흡기증후군 코로나바이러스 변이들의 공통 서열을 포함하는 코로나바이러스감염증-19 범용 백신 조성물 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1270732A1 (en) * | 2001-06-21 | 2003-01-02 | Schuler, Gerold | Improved transfection of eukaryontic cells with linear polynucleotides by electroporation |
| DE102005046490A1 (de) * | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| SG11201405542UA (en) * | 2012-03-27 | 2014-10-30 | Curevac Gmbh | Artificial nucleic acid molecules |
| EP4011451A1 (en) * | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
| CN110520155A (zh) * | 2017-02-28 | 2019-11-29 | 广州纳泰生物医药技术有限公司 | 预防和治疗寨卡病毒感染的rna药物制剂 |
| AU2019275071B2 (en) * | 2018-05-24 | 2022-12-15 | Sirnaomics, Inc. | Composition and methods of controllable co-coupling polypeptide nanoparticle delivery system for nucleic acid therapeutics |
| PH12022551788A1 (en) * | 2020-01-28 | 2024-02-26 | Codagenix Inc | DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOF |
| JP2023512519A (ja) | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
| US12029786B2 (en) | 2020-02-07 | 2024-07-09 | RNAimmune, Inc. | Composition and method of mRNA vaccines against novel coronavirus infection |
| GB202004974D0 (en) | 2020-04-03 | 2020-05-20 | Treos Bio Ltd | Coronavirus vaccine |
| US20210316002A1 (en) | 2020-04-14 | 2021-10-14 | Ut-Battelle, Llc | Compositions and methods for drug delivery and treating viral infections |
| BR112022024662A2 (pt) | 2020-06-03 | 2023-04-04 | Regeneron Pharma | Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2 |
| EP4204015A4 (en) | 2020-08-31 | 2025-01-01 | The Board of Trustees of the Leland Stanford Junior University | Systems and methods for producing rna constructs with increased translation and stability |
| US20250213679A1 (en) | 2020-10-02 | 2025-07-03 | Celsion Corporation | Polynucleotide vaccines and methods of using the same |
| CN115160413B (zh) | 2021-04-06 | 2023-11-14 | 清华大学 | 一种新型冠状病毒疫苗 |
-
2021
- 2021-02-08 US US17/170,876 patent/US12029786B2/en active Active
- 2021-02-08 BR BR112022015626A patent/BR112022015626A2/pt not_active Application Discontinuation
- 2021-02-08 US US17/798,051 patent/US20230108926A1/en not_active Abandoned
- 2021-02-08 EP EP21750867.0A patent/EP4100066A4/en not_active Withdrawn
- 2021-02-08 CN CN202180024212.1A patent/CN115297892A/zh active Pending
- 2021-02-08 WO PCT/US2021/017149 patent/WO2021159118A2/en not_active Ceased
- 2021-02-08 IL IL295360A patent/IL295360A/en unknown
- 2021-02-08 KR KR1020227030556A patent/KR20220143684A/ko not_active Withdrawn
- 2021-02-08 CA CA3167257A patent/CA3167257A1/en active Pending
- 2021-02-08 MX MX2022009688A patent/MX2022009688A/es unknown
- 2021-02-08 JP JP2022548143A patent/JP2023512833A/ja active Pending
- 2021-02-08 AU AU2021216443A patent/AU2021216443A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023512833A5 (https=) | ||
| CN104349794B (zh) | 信使rna的肺递送 | |
| CN115297892A (zh) | 抗新型冠状病毒感染的mRNA疫苗的组合物和方法 | |
| EP3317411B1 (en) | Atp-binding cassette family coding polyribonucleotides and formulations thereof | |
| CN107001627A (zh) | 用于将核酸引入细胞的组合物 | |
| CN118556131A (zh) | 用于蛋白质表达的mRNA及其模板 | |
| WO2016061549A1 (en) | Compositions comprising small interfering rna molecules for prevention and treatment of ebola virus disease | |
| US20220251601A1 (en) | mRNA NANOCAPSULE AND USE IN PREPARATION OF ANTIVIRAL DRUGS | |
| WO2022219607A1 (en) | Codon-optimized nucleotide sequences encoding a coronavirus spike protein and uses thereof | |
| EP4271363A1 (en) | Micellar nanoparticles and uses thereof | |
| US20250313835A1 (en) | Micellar nanoparticles and uses thereof | |
| JP7237825B2 (ja) | 血中におけるｒｎａの安定性の改善剤および投与方法 | |
| CN118178632A (zh) | 针对猫FIPV的M和N抗原构建mRNA和疫苗的方法 | |
| US20240091151A1 (en) | Micellar nanoparticles and uses thereof | |
| JP2022191527A (ja) | 血中で安定なｍＲＮＡ内包ミセル | |
| CA2797567A1 (en) | Compositions and methods for reduced scarring and for treatment of fibrosis | |
| CN118634243B (zh) | Mir2911在制备抗登革病毒denv的药物中的应用 | |
| WO2026080440A1 (en) | Mrna therapy for neurological disorders | |
| WO2024245344A1 (zh) | 预防新型冠状病毒奥密克戎突变株的mRNA疫苗 | |
| WO2025149946A1 (en) | Micellar nanoparticles and uses thereof | |
| EP4722367A1 (en) | Mrna structure platform for protein expression with high efficiency | |
| CN118662522A (zh) | Mir2911在制备抗黄热病毒yfv的药物中的应用 | |
| TW202446958A (zh) | 核酸分子 | |
| WO2026090328A1 (en) | WNT7a MRNA LIPID NANOPARTICLES FOR THERAPEUTIC USES | |
| CN118178633A (zh) | 针对猫FIPV的多抗原mRNA疫苗开发 |